Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
What's New on Antiandrogens?
Description
The discussion focuses on the latest developments in antiandrogen therapies, driven by the need for options with fewer side effects such as reduced libido and concerns surrounding oral finasteride. Key highlights include a study on topical finasteride indicating its efficacy similar to oral finasteride but with significantly lower plasma concentrations, thus reducing sexual side effects. Additionally, new agents such as pirilutamate, clascuteron, and a topical androgen receptor degrader show promise in clinical studies. Clascuteron, in particular, exhibits comparable efficacy to finasteride and is well-tolerated without sexual side effects. Furthermore, research on novel treatments like monoclonal antibodies targeting prolactin, CXCL12 in androgenic alopecia, and interference RNA against androgen receptors are mentioned as upcoming advancements. Various other therapies like intradermal dutasteride, mesotherapy combinations, and oral bicalutamide for women are discussed, emphasizing collaborative approaches in treatment. Overall, the future of antiandrogens looks promising, with ongoing research aimed at enhancing efficacy and safety.
View moreConclusions
- New anti-androgens are being developed due to concerns about side effects from traditional treatments.
- Topical finasteride has shown similar efficacy to oral finasteride with reduced systemic exposure and fewer sexual side effects.
- Pyrilutamide is an androgen receptor antagonist with promising clinical trial results, indicating significant hair growth.
- Clascoterone has comparable efficacy to finasteride and is being further tested in clinical trials with good safety profiles.
- A new topical androgen receptor degrader (GT-20029) shows potential for treating androgenetic alopecia with reduced systemic exposure.
- Prolactin monoclonal antibodies show promise in hair growth stimulation based on animal studies and need further testing in humans.
- CXCL12 neutralization promotes hair growth in models and may provide a new therapeutic approach.
- SAMiRNA targeting the androgen receptor demonstrates effectiveness in hair count increase, requiring weekly treatments.
- Botulinum toxin may enhance local microcirculation and improve hair density in alopecia patients.
- Combination therapies using anti-androgens with other treatments like minoxidil are suggested for better therapeutic outcomes.
- J Eur Acad Dermatol Venereol, 2022 Feb; 36(2): 286-294. PMCID: PMC9297965 Published online 2021 Oct 25. doi: 10.1111/jdv.17738
- Ellis JA, Sinclair R, Harrap SB. Expert Rev Mol Med. 2022; 4(22): 1-11.
- Saceda -Corralo D,Dominguez-Santas M, Vaño-Galvan. Whats new in therapy for male androgenetic Alopecia. Am J Clin Dermatol 2023 Jan; 24(1):15-24.
- Int J Mol Sci. 2024 Feb; 25(3): 1705. PMCID: PMC10855715 Published online 2024 Jan 30. doi: 10.3390/ijms25031705
- Yun SI, Lee SK, Goh EA. Weekly treatment with SAMiRNA targeting the androgen receptor ameliortates androgenetic Alopecia.Sci Rep. 2022 Jan 31;12(1)
- Biomed Res Int. 2020; 2020: 1501893. PMCID: PMC7424364 Published online 2020 Aug 4. doi: 10.1155/2020/1501893
- Int J Trichology, 2017 Jul-Sep; 9(3): 143-145. PMCID: PMC5596657 doi: 10.4103/ijt.ijt_73_16
- J Eur Acad Dermatol Venereol. 2022 Oct;36(10):e806-e808. doi: 10.1111/jdv.18285. Epub 2022 Jun 16.
- Int J Trichology, 2023 Jan-Feb; 15(1): 39-40. PMCID: PMC10251290 PMID: 37305191